Correction: BMC Complement Med Ther 22, 303 (2022)

https://doi.org/10.1186/s12906-022-03767-y

Following publication of the original article [1], the authors reported that some corrections which were indicated in the proof have not been corrected in the published article.

The updated text are given below and the changes have been highlighted in bold typeface.

Background

In 2021, total cost for patients with AD or other types of dementia was estimated to be $321 billion (https://www.alz.org/media/Documents/alzheimers-factsand-figures.pdf).

Discussion

AD is a progressive neurodegenerative disorder that needs multiple therapeutic approaches. In recent years, aromatherapy has been found as an efficient tool to reduce cognitive impairment resulting from the disease [22–24].

The original article [1] has been updated.